Tenax Therapeutics TENX 深 沪
等待开盘 02-06 09:30:00 美东时间
12.36
-0.770
-5.86%
华盛通- 最 高13.2728
- 今 开12.90
- 成交量 23.75万股
- 最 低 12.35
- 昨 收 13.13
- 总市值 5639.25万
- 52周最高 18.38
- 市盈率 静 --
- 换手率 5.21%
- 52周最低 4.63
- 委 比 33.33%
- 总股本 456.25万
- 历史最高 274560.00
- 量 比 1.20
- 振 幅 7.03%
- 历史最低 4.63
- 每 手 1
- 风险率 2.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股牛股 | High Roller暴涨430%！联手Crypto布局预测市场；航天公司Sidus大涨逾20%
High Roller单日暴涨430%！联手Crypto布局预测市场产品；商业航天公司Sidus大涨逾20%，此前获美军SHIELD项目合同>>
01-15 16:04
Tenax Therapeutics Updates Chief Medical Officer Agreement
Tenax Therapeutics ( ($TENX) ) has issued an update. On January 6, 2026, Tenax ...
01-10 06:03
美股大行评级 | 德银首予Coinbase"买入"评级，目标价340美元；AERO获多家机构首予超配评级；大摩维持苹果"超配"评级，目标价升至315美元
今日重点评级关注：巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从9美元升至10美元；摩根大通：上调Recursion Pharmaceuticals评级至"超配"，目标价从10美元升至11美元
2025-12-18 10:54
Guggenheim Maintains Buy on Tenax Therapeutics, Raises Price Target to $25
Guggenheim analyst Seamus Fernandez maintains Tenax Therapeutics (NASDAQ:TENX) with a Buy and raises the price target from $14 to $25.
2025-12-17 20:57
Tenax Therapeutics Announces Result of Prespecifed Blinded Sample Size Assessment
Planned Review of Standard Deviation Demonstrates No Need to Increase Size of Ongoing LEVEL Study (Level study demonstrates no need for size increase; on track for completion in H1 2026, with topline data expected in H2 2026. Global Phase 3 LEVEL-2 study initiated, targeting enrollment completion by end of 2027. These developments highlight ongoing progress in evaluating TNX-103 for treating PH-HFpEF.)
2025-12-17 14:16
Tenax Therapeutics to Participate in Upcoming Investor Conferences
Tenax Therapeutics, a Phase 3 cardiopulmonary therapies company, announced participation in two investor conferences: the 8th Evercore Healthcare Conference on Dec 2 at 4:15 PM ET and Piper Sandler's 37th Healthcare Conference on Dec 4 at 11:30 AM ET. CEO Chris Giordano and CMO Stuart Rich will participate in fireside chats. Live and archived webcasts available on the company’s investor relations webpage. Tenax is developing levosimendan for PH-H...
2025-11-25 12:00
Tenax Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Tenax Therapeutics reported progress on its Phase 3 LEVEL study for TNX-103 in PH-HFpEF, with plans to enroll 230 patients by mid-2026 and initiate the global LEVEL-2 study in 2025. The company also announced a virtual KOL call on November 13, 2025, to discuss PH-HFpEF treatment and TNX-103 programs. Financially, Tenax ended September 2025 with $99.4 million in cash, but reported a net loss of $15.8 million, up from $4.0 million in the prior year...
2025-11-12 21:05
Tenax Therapeutics to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
Tenax Therapeutics, a Phase 3 pharmaceutical company developing novel cardiopulmonary therapies, announced its participation in the Guggenheim 2nd Annual Healthcare Innovation Conference in Boston, November 10-12, 2025. CEO Chris Giordano and CMO Stuart Rich will engage in a fireside chat on November 10 at 4:00 p.m. ET. The presentation will be available via webcast on the company's investor relations webpage. Tenax Therapeutics specializes in de...
2025-11-03 12:00
Tenax Therapeutics Announces European Patent Office Intention to Grant Patent Covering Use of Levosimendan in PH-HFpEF
<p align="justify">Tenax Therapeutics announced that the European Patent Office has notified its intention to grant a patent for intellectual property protection of TNX-103 (oral levosimendan) and other formulations of levosimendan, including its active metabolites, for use in pulmonary hypertension resulting from heart failure with preserved ejection fraction (PH-HFpEF). The patent, once granted, will provide protection in Europe through at leas...
2025-09-16 11:00
Piper Sandler Initiates Coverage On Tenax Therapeutics with Overweight Rating, Announces Price Target of $20
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Tenax Therapeutics (NASDAQ:TENX) with a Overweight rating and announces Price Target of $20.
2025-09-08 18:39
